In another disappointment for Alzheimer’s sufferers, and notably for US pharma major Eli Lilly (NYSE: LLY), disappointing late-stage study results with its lead drug candidate for the condition have been revealed. Lilly’s shares fell as much as 14% on the news, and were down 12.5% at $66.51 mid-morning.
Lilly today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a Phase III study of solanezumab in people with mild dementia due to Alzheimer's disease (AD), adding to failures in two previous studies.
Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo (p=.095), as measured by the ADAS-Cog14 (Alzheimer's Disease Assessment Scale-Cognitive subscale).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze